LANCET
Our case report presents details of the first individual in North America to have symptomatic reinfection with SARS-CoV-2. Similar to observations with the reinfection case in Ecuador,12 our patient showed increased symptom severity in their second infection, whereas the cases from Belgium and the Netherlands11 and Hong Kong10 did not show a difference in severity of symptoms. The mechanisms that could account for a more severe secondary infection can only be speculated. First, a very high dose of virus might have led to the second instance of infection and induced more severe disease.23 Second, it is possible that reinfection was caused by a version of the virus that was more virulent, or more virulent in this patient's context.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30764-7/fulltext
Vaccinerna kommer ej att fungera. Flockimmunitet är ej uppnåbar.
Our case report presents details of the first individual in North America to have symptomatic reinfection with SARS-CoV-2. Similar to observations with the reinfection case in Ecuador,12 our patient showed increased symptom severity in their second infection, whereas the cases from Belgium and the Netherlands11 and Hong Kong10 did not show a difference in severity of symptoms. The mechanisms that could account for a more severe secondary infection can only be speculated. First, a very high dose of virus might have led to the second instance of infection and induced more severe disease.23 Second, it is possible that reinfection was caused by a version of the virus that was more virulent, or more virulent in this patient's context.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30764-7/fulltext
Vaccinerna kommer ej att fungera. Flockimmunitet är ej uppnåbar.
Skapa ett konto eller logga in för att kommentera
Du måste vara medlem för att kunna kommentera